Biotech Values

[daved]

MCU/MPH.TO Made a call to Medicure today. They had implied that the P3 trial SPA included the primary definition of MI as peak CK-MB >100 ng/ml. I confirmed that this was true and also that only combined cardiovascular death + MI was the primary endpoint.

That takes stroke and the narrower definition of MI out of the picture in P3. The 900 patient P2 trial results would have been easily stat-sig with that endpoint. To me this makes the 3000 patient P3 a slam dunk. The P3 ends in December and should be reported in March 2008. MC1 is fast tracked. This means we can expect it to hit the market in early 09. That's fast.

Hogan indicated that they expected deep penetration in the CABG market which represents over 467,000 procedures per year.

This P3 will cost upwards of 35 mil. They actively seek partners for MC1 alone and in combination with other cardiac care drugs.

They have a nice looking pipe and I like the Aggrostat deal.

I tripled my position today.

Check it out.

Dave